Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionStiles Financial Services Inc
Latest Disclosed Ownership3,650 shares
Latest Disclosed Value $ 2,819,828
Stiles Financial Services Inc reports 9.00% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 30, 2026 - Stiles Financial Services Inc filed a 13F-HR form disclosing ownership of 3,650 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $2,819,828 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 4,011 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -9.00% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F REGENERON PHARMACEUTICALS COM Stock 75886F107 3,650 -361 -9.00 2,820 -8.92 0.8617
2026-02-03 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,011 -342 -7.86 3,096 26.48 0.9531
2025-10-30 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,353 -5 -0.11 2,448 6.86 0.7718
2025-07-24 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,358 262 6.40 2,291 -11.86 0.7911
2025-04-22 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,096 200 5.13 2,599 -6.34 0.9976
2025-01-28 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,896 464 13.52 2,774 -23.07 1.0043
2024-10-31 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,432 89 2.66 3,606 2.68 1.2701
2024-08-01 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,343 64 1.95 3,512 11.32 1.3509
2024-04-30 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,279 246 8.11 3,156 18.48 1.2646
2024-01-26 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,033 334 12.37 2,664 19.90 1.2096
2023-11-08 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,699 753 38.69 2,221 58.87 1.1518
2023-07-21 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,946 571 41.53 1,398 23.83 0.6947
2023-05-11 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,375 385 38.89 1,130 58.12 0.6068
2023-01-27 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 990 990 714 0.4083
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.